Erickson and colleagues evaluated hydration requirements with emetogenic chemotherapy and investigated the effects of an antiemetic drug combination.
Authors discuss the results of this observational real-world study and how sequencing tyrosine kinase inhibitors can extend chemotherapy-free treatment time.
In this review article from Future Oncology find out about the PACIFIC trial design as well as the future of immunotherapy combinations and biomarkers beyond PD-L1.
A new study, published in CNS Oncology estimates the survival benefit of adding tumor treating fields and temozolomide for newly diagnosed glioblastoma patients.
Immune checkpoint inhibitors revolutionized the treatment of non-small-cell lung cancer, although their costs are a limitation; find out more in this article from Immunotherapy.
This database study demonstrates variations in the utilization of hematopoietic cell transplantation in adult patients with acute lymphoblastic leukemia based on several biological and non-biological factors.
Find out more about the utility of clinical characteristics in the selection of patients with advanced NSCLC as potential candidates for single-agent anti-PD-1/PD-L1 immunotherapy in this open access Future Oncology review article.
Find out about the healthcare utilization and costs associated with diffuse large B-cell & follicular lymphoma patients treated in the US in this research article from Future Oncology.
In this new article published in Future Oncology, Ottoboni et al. report on the safety of a novel and recently FDA-approved polysorbate 80‒ and synthetic surfactant‒free intravenous formulation of the neurokinin 1 receptor antagonist aprepitant (HTX-019).
Discover the case of nivolumab-induced synchronous occurrence of myositis and hypothyroidism in a patient with squamous cell lung cancer in this article from the impactful journal Immunotherapy.